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Abstract 15 
Objectives: The aim of this study was to determine if there are differences in cellular 16 
changes in cavalier King Charles spaniel (CKCS) myxomatous mitral valves 17 
compared to non-CKCS dogs. 18 
Animals: CKCSs (n=6) and age-matched mixed breed (n=6) with severe MMVD, and 19 
normal mixed breed (n=4) dogs. 20 
Methods: Immunohistochemistry staining and qualitative and quantitative analysis of 21 
mitral valves sections, examining for the presence of CD11c and CD45, vimentin, 22 
alpha smooth muscle actin (α-SMA) and myosin heavy chain 10 (Smemb), 23 
vonWillebrand factor (vWF) and CD31 and Ki-67.  24 
Results: Vimentin positive cell numbers were increased in the MMVD dogs and 25 
distributed throughout the valve with greatest density close to the endothelium. There 26 
were no significant differences in cell marker expression for the two diseased groups, 27 
but cell numbers were significantly increased compared to controls for α-SMA 28 
(CKCS only) and SMemb (CKCS and mixed breed)  (P<0.05).  α-SMA+ cells were 29 
primarily located at the valve edge, with Smemb+ cells similarly located, but also 30 
present throughout the valve stroma. A small number of cells close to the valve edge 31 
co-expressed α-SMA and SMemb. Endothelial vWF expression was identified in all 32 
valves, with evidence of disrupted endothelium in the diseased, but was also found in 33 
diseased valve stroma. There was no staining for CD11c, CD45 or CD31 in any valve. 34 
Ki-67+ cells formed linear clusters at the leaflet tip and were sparsely distributed 35 
throughout both myxomatous valve groups. 36 
Conclusions: The cellular changes notes with advanced stage MMVD are appear 37 
similar for CKCS when compared to mixed breed dogs. 38 
 39 
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Abbreviations: 41 
CKCS      cavalier King Charles spaniel 42 
MMVD     myxomatous mitral valve disease 43 
5-HT     5-hydroxytryptamine (serotonin) 44 
α-SMA    alpha smooth muscle actin 45 
VIC     valve interstitial cell 46 
MYH-10    myosin heavy chain 10 (SMemb) 47 
Non-muscle embryonic myosin  SMemb (MYH-10) 48 
VEC     valve endothelial cell 49 
PBS      phosphate-buffered saline 50 
vWF     von Willebrand Factor 51 
DAPI     4',6-diamidino-2-phenylindole 52 
ANOVA      one-way analysis of variance 53 
 54 
Introduction: 55 
The cavalier King Charles spaniel (CKCS) breed is recognised to be particularly pre-56 
disposed to the development of myxomatous mitral valve disease (MMVD) in terms 57 
of age of onset, progression and severity1-3. MMVD is highly heritable in the CKCS 58 
breed and it is reasonable to suppose heritability also has a role in disease appearance 59 
and progression 4,5. There are CKCS-specific traits such as differences in platelet 60 
numbers and platelet aggregation tendency and higher serum magnesium and 5-HT 61 
(serotonin) levels compared to other dogs that have been examined for correlation 62 
with development of MMVD, with varying results6-12. Furthermore, the CKCS is 63 
more predisposed to chronic fibrosing pancreatitis and syringomyelia than other 64 
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breeds and with MMVD this might reflect a breed-specific global connective tissue 65 
abnormality13-15. While there is no clear causal link established between these findings 66 
in the CKCS and MMVD it still points towards breed-specific phenotypic 67 
characteristics that might have bearing on disease appearance. 68 
 69 
Cellular changes that occur with MMVD are well described. There is an increase in α-70 
smooth muscle actin (α-SMA) positive valve interstitial cells (activated 71 
myofibroblasts, aVICs) which locate mainly towards the valve distal free-edge (valve 72 
tip) and appears to be related to disease severity16-19. It is activation of the VICs that is 73 
believed to drive the extra-cellular matrix damage seen in MMVD through a 74 
combination of increased catabolic activity and aberrant repair and replacement. In 75 
normal valve stroma the majority of cells are quiescent vimentin-positive VICs 76 
(qVIC), with a few desmin-positive cells 16, 17. In overtly myxomatous areas of 77 
affected valves some cells also appear to be activated myofibroblasts or with 78 
increased differentiation capacity based on their expression of myosin heavy chain-10 79 
(MYH-10; non-muscle embryonic myosin, SMemb), with appearance of cells in 80 
clusters close to the endothelium and deeper in the valve stroma20, 21. There is no 81 
evidence that there is active cell proliferation and while some cells exhibit a pro-82 
apoptotic status they do not undergo programmed cell death16, 22. However, there are 83 
regional changes in cell numbers; reduced in overtly myxoid stroma and increased in 84 
sub-endothelial zones21.  A small increase in mast cell numbers is also noted, but there 85 
is no increase in macrophages numbers and no inflammatory cells are reported16, 17. 86 
Changes in endothelial cell morphology, coupled with endothelial cell (VEC) loss are 87 
also reported16, 23, 24. Changes include increased expression of endothelin receptors, 88 
evidence of VEC activation, apoptosis, basement membrane loss and damage with 89 
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cell detachment 25,26. The interaction between the VECs and VICs in the context of the 90 
pathogenesis of MMVD is not understood, but the characteristic accumulation of 91 
activated myofibroblasts close to the endothelium and in particular areas of damaged 92 
endothelium suggest some sort of interaction does occur 26.  93 
 94 
Of the studies to date, all have presented data from a mix of pedigree and cross-bred 95 
dogs. Considering the susceptibility of the CKCS to MMVD, the aim of this study 96 
was to determine if there are differences in valve cellular changes in the CKCS 97 
compared to non-CKCS dogs examining the resident valve interstitial and endothelial 98 
cells, to confirm the cell changes noted in previous studies and also examine again for 99 
the possible presence of inflammatory cells and macrophages.  100 
 101 
Animals, Materials and Methods: 102 
Tissue samples 103 
Anterior mitral valve leaflets were obtained from six elderly CKCS (12-14 yr; 2 104 
neutered females & 4 neutered males; 8-12 Kg) and six mixed breed dogs (8-12 yr; 3 105 
neutered females & 3 neutered males; 10-18Kg) with MMVD. Control samples were 106 
obtained from four young adult mixed breed dogs (1-2 yr; 2 intact males & 2 neutered 107 
females; 12-15kg) with no evidence of disease. All samples were collected with full 108 
owner consent and the study conformed to national (UK) and institutional ethical 109 
guidelines for the use of animals in research. Valves were removed within minutes of 110 
death, gently washed with phosphate-buffered saline (PBS), immersed in 4% 111 
paraformaldehyde and stored at 4o C for 36 hr. Samples were then rinsed in PBS and 112 
stored in 70% ethanol at 4o C until required. Valves were pathologically graded 113 
Whitney Grade 3 or 4 by at least two of the authors independently at the time of 114 
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collection and then a grade agreed (C-CL, BMC, M-ML & GJC)27. Representative 115 
samples of similar gross pathological appearance were cut from each valve, paraffin-116 
embedded and 4 consecutive 5 µm sections were collected onto coated slide. Whole 117 
valve length and distal transverse sections were collected for longitudinal and 118 
horizontal evaluation. Sections were de-waxed in xylene and re-hydrated through 119 
serial ethanols and distilled water.  120 
 121 
Immunohistochemistry 122 
Immunohistochemical staining used a combination of a standard peroxidase method 123 
(qualitative) with NovaRedc as chromagen (ABC Elite Kit, Vector), and indirect 124 
immunofluorescence (qualitative and quantitative) using fluorescent dyes conjugated 125 
to IgGd (AlexaFluor488 and 568, Invitrogen). Double staining was carried out for α-126 
SMA and SMemb using indirect immunofluorescence to determine if there was co-127 
localisation. For double staining Images were collected using the two different 128 
fluorescence channels and then merged. Sections were examined using fluorescence 129 
and light microscopye (Leica-DMRB) for the presence of the universal mesenchymal 130 
cell marker vimentin, the inflammatory cell markers CD11c (macrophage, monocytes) 131 
and CD45 (hematopoietic cells, T-cell lymphocytes), the valve endothelial cell (VEC) 132 
markers vWf and CD31, the activated myofibroblasts (aVIC) markers α-smooth 133 
muscle actin (α-SMA), myosin heavy chain-10 (SMemb) and the cell proliferation 134 
marker Ki67. The details for each antibody are shown in Table 1. For antigen retrieval 135 
sections were microwaved either in citrate buffer (0.01 M, pH 6.0) or Tris-EDTA 136 
(10mM Tris base, 1 mM EDTA solution, pH 8.0).  137 
 138 
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For the peroxidase technique sections were incubated with 1% hydrogen peroxide 139 
(H2O2 in phosphate-buffered saline (PBS pH 7.4) for 10 min and blocked with 10% 140 
goat serum (diluted in 0.5% Tween 20)f) (Vector Laboratories Inc.) for 30 min at 141 
room temperature. Sections were then incubated for 60 min at room temperature with 142 
primary antibodies, rinsed in 0.5% Tween20 in PBS and incubated for 30 min at room 143 
temperature with biotinylated secondary antibodies (goat anti-mouse or anti-rabbit 144 
IgGf; Vector Laboratories Inc.). Slides were counterstained with haematoxylin, 145 
dehydrated through graded ethanols and xylene and mounted in a xylene-based 146 
mediumg (DePex; Gurr-BDH Chemicals Ltd). For each dog a minimum of four 147 
sections were examined for each antibody. 148 
 149 
For immunofluorescence, the basic protocol was the same for the peroxidase 150 
technique, without addition of H2O2, and the secondary antibody was applied for 60 151 
min at room temperature in a dark humid chamber. Slides were washed in PBS (3 152 
times for 5min), mounted and nuclear counterstained with DAPI mount (Vectashield). 153 
Positive controls included canine spleen (CD11c and CD45), lymph node (CD11c and 154 
CD45) and duodenum (Ki67, CD31, vWF, vimentin α-SMA and Smemb), and for 155 
negative controls the primary antibody was omitted. Images were taken using a light 156 
microscope with fluorescent capabilitye (Leica-DMRB). 157 
 158 
Image capture and analysis 159 
For quantitative assessment (ImageJ cell counter plug-inh; National Institutes of 160 
Health) nine randomly selected (x400 magnification) non-overlapping images were 161 
digitally captured, beginning close to the valve edge (tip of leaflet) and moving back 162 
to the junction with the atrial myocardium where the valve base (zone adjacent to the 163 
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annulus) covering the same region of interest for each valve, and the cells were then 164 
counted manually. Qualitative descriptive assessment only was carried out on the 165 
NovaRed stained sections (longitudinal and horizontal) and qualitative and 166 
quantitative assessment on the fluorescent labelled sections (longitudinal only).  167 
 168 
Statistical analysis 169 
Data were expressed as mean ± standard deviation of the mean. Since the sample size 170 
was small log transformation was undertaken to achieve normality, followed by the  171 
D'Agostino-Pearson normality test, and inferential statistical analysis applied using 172 
one-way analysis of variance (ANOVA) testing with a p value of <0.05. Where one-173 
way analysis of variance (ANOVA) detected significant difference, inter-group 174 
differences were compared using the post-hoc Tukey Simultaneous test. 175 
 176 
Results: 177 
Gross and histological changes in myxomatous mitral valves from CKCS and non-178 
CKCS were not appreciably different, and not dissimilar to previous reports 21,27.  179 
 180 
Cellular changes in myxomatous mitral valve disease 181 
Similar changes in the distribution of immunoreactive cells were noted for 182 
longitudinal and horizontal sections. In the normal mitral valves, most cells were 183 
vimentin positive and evenly distributed, and presumed to be quiescent VICs. In the 184 
diseased valves, vimentin positive cells were also evenly distributed, but the highest 185 
density was adjacent to the endothelial layer (Fig. 1). No cell staining was observed in 186 
any valve for the inflammatory cell markers CD11c or CD45, but positive staining 187 
was found in control lymph node. In normal mitral valves very few α-SMA or 188 
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SMemb+ cells were seen and these were typically located adjacent to the 189 
endothelium. In diseased valves α-SMA+ cells were generally found lying beneath the 190 
endothelium, clustering mostly at the distal free-edge with a few cells present in the 191 
valve stroma. SMemb positive cells were also found clustering surrounding the 192 
myxomatous areas and close to the distal free-edge, but there was positive staining 193 
throughout the leaflet depth. There were no clear differences comparing CKCS and 194 
the mixed breed dogs (Fig. 1). vWF+ endothelial cells were found along the whole 195 
leaflet length, but with areas of discontinuity in the diseased dogs. A consistent 196 
finding in both diseased groups (5/6 CKCS; 6/6 mixed breed) was clusters of vWF+ 197 
cells in the myxomatous sites away from the valve edge (Fig 2). No CD31+ cells were 198 
seen in any test or control sample. We have been unsuccessful in identifying CD31 199 
positive cells in any canine paraformaldehyde fixed tissues, but have found this 200 
antibody to be effective in canine valve endothelial cell cultures. 201 
 202 
Ki-67+ cells formed linear clusters typically at the leaflet tip, but also were distributed 203 
sparsely throughout the myxomatous valves of both groups (Fig 2). Staining appeared 204 
to be a combination of cytoplasmic and nuclear. This sparse distribution was 205 
somewhat similar to that seen for α-SMA and SMemb+ cells, but cell counting was 206 
not feasible. In affected valves, flattened elongated cells at the valve surface 207 
(presumed to be VECs) also showed positive staining for Ki-67.   208 
 209 
Immunofluorescence; Qualitative and Quantitative Analysis  210 
The total numbers of cells positive for α-SMA was significantly increased in the 211 
CKCS group compared to normal (Table 2) (p<0.05). SMemb+ cells were 212 
significantly increased in the two diseased groups compared to normal (p<0.05). 213 
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Vimentin+ cells made up the largest number in all valves, and cell numbers in both 214 
diseased valves approached twice that seen in normal valves (Table 2; Fig. 3). While 215 
the pattern of staining for α-SMA and SMemb at the valve edge was similar in both 216 
affected groups, only a few of those cells co-expressed both antigens (Fig. 3 & Fig. 4). 217 
In overtly myxomatous areas, the overall pattern of cellular staining was similar in the 218 
CKCS and mixed breed dogs.  219 
 220 
Discussion: 221 
The cavalier King Charles spaniel (CKCS) breed predisposition to MMVD is well 222 
recognised and heritability has a role in disease appearance and progression4,5. There 223 
are some CKCS-specific traits identified and while their association with MMVD can 224 
be unclear, it is reasonable to suggest that disease phenotype and pathology might be 225 
different to that seen in other dogs7-11. By assessing for a range of markers for 226 
inflammation, proliferation and mesenchymal cell phenotypic differentiation evidence 227 
was found that cell changes in the CKCS valve are fundamentally the same appear to 228 
be similar to that seen in mixed breed dogs.  229 
 230 
There was no evidence of inflammatory cells in any of the samples examined and this 231 
is in agreement with the only other report 16. Small numbers of macrophages and mast 232 
cells have been previously found in MMVD valves and there  is an increased 233 
expression of some inflammatory cytokine transcripts in affected valves, but there still 234 
is no clear evidence that inflammation has an important role in this disease  17, 28,29. 235 
 236 
Appearance of activated of α-SMA+ valve interstitial cells in canine MMVD is well 237 
recognised, particularly in the distal portion of the valve and close to the valve edge, 238 
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and this was again noted in the present study in all affected dogs 16, 17. Increased α-239 
SMA+ cells numbers were seen in the two affected groups and were moderately 240 
higher in the CKCS valves, but this could be a chance finding. Increased numbers of 241 
α-SMA+ cells is dependent on disease severity and the dogs in the current study were 242 
aged and had the most severe form of the disease 19. Increased SMemb+ cell numbers 243 
have also been previously reported and were found again to be increased in this study, 244 
with a marginally higher number in the non-CKCS dogs 16. The distribution of 245 
Smemb+ cells in the valve stroma possibly identifies a cell population with 246 
differentiation potential, but the presence of Ki-67 expression would suggest 247 
proliferation is on-going as well.  Lastly, using vimentin as a general mesenchymal 248 
cell maker, total cell numbers in the two affected groups were similar and were 249 
approximately twice that of the normal valves. Reports to date on changes in cells 250 
numbers are either equivocal or conflicting, but this is likely to be based on the 251 
counting techniques used. In myxoid stroma cell numbers decline, but overall cell 252 
numbers increase and this is dominated by increased cell numbers in the atrialis layer 253 
15,21. The current study furthermore confirms there is an overall increase in interstitial 254 
cell numbers when the entire valve length is examined. However, it should be noted 255 
the normal valves were not age-matched and increased cell numbers associated with 256 
aging cannot be discounted.  The lack of age-matched normal controls is a study 257 
limitation, but it is understood that finding normal mitral valves in aged dogs is not 258 
readily achievable. 259 
 260 
While vimentin expression is widespread in many cell types, interstitial cells 261 
expressing vimentin are generally considered to be a quiescent phenotype form of 262 
VIC in the normal mitral valve 16, 17, 21. In the diseased valve cells retaining vimentin 263 
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expression alone, or expressing one or both of the two activation/differentiation 264 
markers (α-SMA and SMemb), may represent an expanded population available for 265 
phenotypic alteration in response to appropriate triggers. There was an increased 266 
expression of the cell proliferation marker Ki-67 in the MMVD valves and this was 267 
most noticeable where there was the largest number of α-SMA positive cells close to 268 
the distal free-edge. This finding contrasts with the only other study where Ki-67 269 
showed minimal expression in diseased valves 16. Additionally the similar regional 270 
expression of Ki-67 with α-SMA+ cells would might suggest proliferation of 271 
activated myofibroblasts close to the valve edge is more likely than migration of these 272 
cells from deep in the valve stroma, and it would be reasonable to suggest this 273 
proliferation is in response to the endothelial changes and damage noted with MMVD 274 
26. Co-localisation staining would confirm if this was the case. Under normal 275 
circumstances VECs and VICs interact to prevent VIC activation and VEC 276 
endothelial-to-mesenchymal transition (EndoMT) (the process by which endothelial 277 
cells invade tissue and differentiate into a mesenchymal phenotype) thereby 278 
maintaining a quiescent state 30. However, up-regulation of genes associated EndoMT 279 
is found in affected canine valves, suggesting changes in cellular homeostasis occurs 280 
with disease progression 30,31. EndoMT is likely to be one mechanism that contributes 281 
to accumulation of α-SMA positive cells close to the endothelium. 282 
 283 
Identification of cells positive for aα-SMA and Smemb and the distribution of these 284 
cells has been previously reported, but the identification of co-localisation is a novel 285 
finding16,17,21.  This co-localisation of α-SMA and SMemb in a small number of cells 286 
close to the valve edge identifies a population that have greater differentiation 287 
potential than those expressing α-SMA or SMemb alone, with Smemb having 288 
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important functions in cell adhesion and cell migration.. Such cells are believed to 289 
have greater phenotypic differentiation capability in response to injury32. In the case 290 
of MMVD, a similar capacity for phenotypic versatility might exist where endothelial 291 
damage has occurred. 292 
 293 
VonWillebrand factor expression demonstrated the presence of the endothelium in all 294 
valves and confirmed the loss of endothelial cells along some sections of affected 295 
valve edges. Endothelial damage and denuding is now recognised to be a cardinal 296 
feature of MMVD, and might be a major triggering event driving the phenotypic 297 
changes seen with VICs and proliferation of aVICs close to the valve edge 2, 23, 24. The 298 
localised expression of vWF in cells within the stroma of the diseased valves was an 299 
un-expected finding, suggesting either migration of endothelial cells or mesenchymal 300 
transition of stromal VICs (mesenchymal to endothelial transition). The localisation of 301 
Smemb+, vWF+ and Ki-67+ cells in the stroma might support the latter conclusion. 302 
This finding might be due to extravasation during sample collection, but the number 303 
of cells and consistency of the finding make this less likely. Successful staining for 304 
CD31 would have been useful to clarify the endothelial identity or not of these cells, 305 
as would double staining to identify co-localisation.  Lastly, while there appears to be 306 
a common pathological end-point when comparing MMVD in CKCSs and mixed 307 
breed dogs this does not presume a shared pathogenesis, although that would not be 308 
an unreasonable to presume so conclusion. 309 
 310 
The main limitations of this study is the sample size (a recognized problem with 311 
studies of this nature) and the technical problem of comparative sampling from 312 
normal and diseased valves that have markedly different geometry. The laminated 313 
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structure of the normal valve compared to the loss of lamination in the disease valves 314 
is also a confounding factor. Lastly, while there appears to be a common pathological 315 
end-point when comparing MMVD in CKCSs and mixed breed dogs this does not 316 
presume a shared pathogenesis, although it would not be unreasonable to presume so.  317 
 318 
In conclusion, this study confirms that there is no evidence for inflammatory cell 319 
involvement in canine MMVD, that the cell changes are similar appear similar for 320 
CKCS as for other dogs, and that the changes in cell numbers in MMVD are possibly 321 
due to cell proliferation. This study suggests MMVD is not a heterogeneous disease, 322 
at least in terms of cellular changes and that the CKCS form of the disease differs 323 
only in its time of onset and speed of progression.  However, the pathogenesis of 324 
MMVD is unknown and it is possible different mechanisms could result in the same 325 
end-stage findings. However, for now it seems it is the temporal presentation and not 326 
the end-stage pathology that is likely to be the heritable feature of MMVD in the 327 
cavalier King Charles spaniel. Furthermore, it From these studies it would be 328 
reasonable to presume that studies of any dog with MMVD are applicable to all dogs 329 
and breeds.  330 
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Table 1. Antibody source and concentration used for IHC in canine mitral valves. 470 
 471 
Primary and 
Secondary 
Antibodies 
Origin Dilution Manufacturer Catalogue 
No. 
α-SMA Mouse monoclonal 1:400 Sigma A2547 
SMemb Rabbit polyclonal 1:1000 Abcam Ab24761 
Vimentin Mouse monoclonal 1:1600 Sigma V6389 
vWF Rabbit polyclonal 1:1000 Abcam Ab6994 
Ki-67 Rabbit polyclonal 1:200 Abcam Ab15580 
CD11c Mouse monoclonal 1:100 Abcam Ab76911 
CD45 Mouse monoclonal 1:100 AbD Serotec MCA2035S 
CD31 Rabbit polyclonal 1:100 Abcam Ab28364 
Alexafluor 488 Goat anti-Mouse IgG 
(H+L) 
1:100 Invitrogen A10667 
Alexafluor 568 Goat anti-Rabbt IgG 
(H+L) 
1:100 Invitrogen A11011 
Biotinylated 
Antibody 
Goat anti-Mouse IgG 
(H+L) 
1:1000 Vector BA-9200 
Biotinylated 
Antibody 
Goat anti-Rabbit IgG 
(H+L) 
1:1000 Vector BA-1000 
 472 
 473 
474 
20 
 
Table 2. Comparison of cell numbers (mean +/-SD) positive for α-smooth muscle 475 
actin (α-SMA), embryonic smooth muscle myosin (Smemb) and vimentin in mitral 476 
valves of cavalier King Charles spaniels (CKCS n=6), mixed breed dogs (n=6) with 477 
myxomatous mitral valve disease (MMVD) and normal mixed breed dogs (n=4). Data 478 
log transformed. * Significantly different from control group P<0.05. 479 
 480 
 
α-SMA (Mean±SD) 
 
Smemb 
(Mean±SD) 
 
Vimentin 
(Mean±SD) 
 
CKCS 
n=6 
33.95±12.13* 
 
23.13±5.72* 
 
40.52±18.41 
 
non-CKCS 
n=6 
25.7±2.67 
 
29.55±3.06* 
 
46.95±17.65 
 
Control 
n=4 
10.75±2.95 
 
14.53±3.96 
 
26.75±7.24 
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Figure 1. Immunohistochemistry of myxomatous mitral valves from cavalier King 483 
Charles spaniels (CKCS; Left Panel A, B & C) and non-CKCS (Right Panel D, E & 484 
F). Photomicrographs for immunostaining of vimentin (A&B) alpha-smooth muscle 485 
actin (α-SMA; C&D) and myosin heavy chain-10 (Smemb; E&F) in the distal zone. 486 
There is a similar aggregation pattern of α-SMA, SMemb, and vimentin in CKCS and 487 
non-CKCS with positive cells forming linear clusters along the valve edge most 488 
noticeable with α-SMA . Magnification α-SMA, SMemb, Vimentin 20x, bar = 50μm. 489 
 490 
Figure 2.  Photomicrographs of Von Willebrand Factor (vWF) immunostained 491 
myxomatous mitral valves (vWF; right panel A-C) and Ki-67 (left panel D-F). (A) 492 
Continuous layer of endothelium showing expression of vWF, compared with (B) 493 
interrupted endothelium. (C) Spindle-shaped vWF positive cells clustering in the 494 
spongiosa. (D) Multi-layered Ki-67 positive cells aggregating in the myxomatous 495 
region at the distal end of mitral valve leaflets. (E) Clusters of Ki-67 positive cells in 496 
the spongiosa. (F) Single layer of endothelial cells showing positive staining for the 497 
proliferation marker Ki-67. Magnification (A-D) 20x, Bar = 50μm, (E) (F) 40x, Bar = 498 
25 μm. 499 
 500 
Figure 3. Fluorescence photomicrograph of cavalier King Charles spaniel 501 
myxomatous mitral valve, taken at the level of the valve edge. Immunofluorescence 502 
staining for alpha-smooth muscle actin (α-SMA), myosin heavy chain-10 (Smemb), 503 
Vimentin, and 4-6-diamidino-2- phenylindole (DAPI, blue) nuclear counterstaining. 504 
Magnification 40x, scale = 25 μm. 505 
 506 
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Figure 4. Double fluorescence photomicrographs of cavalier King Charles spaniel 507 
myxomatous mitral valve, taken at the level of the valve edge. Alpha-smooth muscle 508 
actin (α-SMA; green) and myosin heavy chain-10 (Smemb; red). There is a different 509 
staining pattern of α-SMA and SMemb positive cells. The merged photomicrographs 510 
show occasional cells co-expressing α-SMA and SMemb (arrows). Magnification 511 
40x, scale = 25 μm. 512 
 513 
Footnotes: 514 
c. ABC Elite Kit, Vector Laboratories Inc. 515 
d. AlexaFluor488 and 568, Invitrogen 516 
e. Leica-DMRB 517 
f. Vector Laboratories Inc. 518 
g. DePex; Gurr-BDH Chemicals Ltd 519 
h. National Institutes of Health 520 
 521 
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